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and complementary roles of aggrecanase activity and MMP
activity in human joint aggrecanolysis
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Summary
Our understanding of aggrecanolysis in the human joint has recently been clariﬁed by detailed analysis of naturally occurring intermediates in
cartilage and synovial ﬂuids. The most studied aspect has been the proteolysis of the interglobular domain (IGD) of aggrecan with release of
the glycosaminoglycan (GAG)-attachment regions, because this appears to be most destructive to tissue function. In this Editorial review,
a working model is presented which supports the view that one or more aggrecanases (ADAMTS 1, 4, 5, 8, 9, 15) are responsible for cleavage
of the IGD with destructive loss of tissue GAG. In contrast, one or more metalloproteinases (MMPs) (MMP 1, 2, 3, 7, 8, 9, 10, 13, 14, 19, 20)
are responsible for cleavage of the IGD (at Asn360ePhe361) within a separate pool of aggrecan, which does not bear GAG, because it has
previously been C-terminally truncated in a separate slow turnover process. These ﬁndings, along with recent gene deletion studies in mice,
suggest that ADAMTS-mediated aggrecanolysis is destructive to cartilage function whereas MMP-mediated aggrecanolysis may actually be
beneﬁcial.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Depletion of aggrecan from the cartilage matrix has been
called a ‘‘cardinal feature’’ of joint diseases such as osteo-
arthritis (OA). Such diminution can be minor, it may be con-
ﬁned to certain focal regions or it can be part of the
widespread tissue destruction in late stage irreversible dis-
ease. It may occur ﬁrst in the superﬁcial zone of the tissue
and has often been described as beginning in a pericellular
location, consistent with an important role for the resident
chondrocytes in the process. Dissipation of aggrecan low-
ers the ﬁxed charge density of the tissue microenvironment,
which in turn is thought to initiate the cascade of events
(chondrocyte proliferation, exposure of cells to anabolic
and catabolic mediators), which accompany collagenolysis
and irreversible tissue disruption. With a view to therapeutic
intervention, there has been much research devoted to un-
derstanding the mechanism(s) of aggrecan depletion. Such
research has acknowledged the likely role of anabolic
change but has also lead to the view (see Ref.1 for review)
that the problem is primarily due to an accelerated rate of
aggrecanolysis which ‘‘overwhelms’’ the ability of the tissue
to provide biosynthetic replacement.
The debate over metalloproteinases (MMPs)
vs aggrecanase
Early research on cartilage aggrecanolysis was based on
data (Ref.2 amongst many others) suggesting that one or
* Tel: 1-813972250; Fax: 1-8139757127; E-mail: jsandy@
shctampa.usf.edu95more members of the MMP family of proteinases were
involved. This followed from the burgeoning interest in
MMPs as matrix-degrading enzymes and also from the
persuasive logic that aggrecanolysis would likely be
catalyzed by members of the collagenase family. Thus,
the collagenases (MMP-1, MMP-8 and MMP-13) had
been shown very early3 to be capable of destructive
cartilage collagenolysis. The discovery4e6 of a cartilage
endoproteinase with an unusual Glu-X cleavage preference
led to the identiﬁcation (Ref.7 among others) of ADAMTS 1,
4, 5, 8, 9, 15 as primary aggrecanases. This catalyzed an
active debate over the relative importance of MMPs and
aggrecanases in cartilage aggrecan degradation in model
systems8e12 and in human arthritis13e15.
This debate continues with the publication of an important
new paper by Struglics et al.16 in Osteoarthritis and
Cartilage.
Aggrecan structure and proteolysis
Aggrecan is present in cartilage as a multimer in which
the monomer is retained by interaction with hyaluronan
and link protein through the aggrecan N-terminal globular
domain (G1). The G1 domain is attached to the remainder
of the molecule (G2 domain, keratan sulfate and
chondroitin sulfate rich regions and G3 domain) through
a linear peptide of 150 amino acids (the interglobular
domain, IGD), which is particularly sensitive to proteolytic
attack probably due to its linear stiffened structure17.
Since any single cleavage of intact aggrecan in the IGD
(see Fig. 1 for details of cleavage sites) is known to
release the complete glycosaminoglycan (GAG)-rich
region from the tissue, this 150 amino acid stretch has
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Fig. 1. Cleavage sites identiﬁed in the IGD of aggrecan. This diagram depicts the IGD (straight line) connecting the globular G1 domain and G2
domain (shaded circles). The sites of MMP-mediated and ADAMTS-mediated cleavage are shown above the line and the sites for other
proteinases below the line. Arrows point to the scissile bond in each case (see footnote a for detailed explanation of residue numbering).been a major focus of arthritis-related research in this
areaa.
Aggrecanolysis in vivo
Nine different IGD cleavage sites have been demonstrated
(by N-terminal sequencing) to occur in incubations of aggre-
can with puriﬁed proteinases. Signiﬁcantly, only two cleav-
ages (marked with heavy black arrows in Fig. 1) appear
to occur in human tissues in vivo. These are the so-called
MMP-site (N360-F361) and the aggrecanase site (E392-
A393). These in vivo cleavages (see Fig. 2) generate natu-
ral products with novel terminals which were ﬁrst identiﬁed
by protein chemistry methods including Edman degradation
and peptide mapping with mass analysis18,19. In the late
1980s, a ‘‘neoepitope’’ antibody strategy was developed20
to detect new terminal sequences in cleaved proteins.
This approach was soon applied to cartilage matrix21 and
it has since become a major tool in arthritis research22.
The results which set the stage for a debate
Before discussing the interesting new data from Struglics
et al.16, it is useful to review the seminal observations which
underpin the debate. While this topic has been studied in
many animals, tissue and cell culture systems the current
comments are restricted to data generated with human ma-
terial. Evidence for human MMP cleavage products (Fig. 2,
lower section) was ﬁrst described in 199219 in a study where
G1-VDIPEN was identiﬁed in human cartilage extracts by
C-terminal peptide isolation. This was conﬁrmed by the
use of neoepitope antibodies to FVDIPEN36023 in human
cartilages from normal, OA and RA patients14. Next,
a monoclonal Ab (AF-28) to the 361FFGVGG terminal dem-
onstrated the presence in unfractionated human synovial
a The new residue numbering scheme adopted in this Editorial,
and introduced in recent detailed cartilage aggrecanolysis stud-
ies28,38, is different by a value of 19 from that used for much of
the published work in this area. The new numbering is taken directly
from the data provided in NCBI. This change has been made to sim-
plify all numbering of aggrecan samples from the wide range of spe-
cies now under study. The original numbering ( for example
VDIPEN341 and NITEGE373) was developed to accommodate
the ﬁnding39 that the natural N-terminal of porcine aggrecan is
VEVS and this corresponds to 20VETS in human aggrecan40.
The ﬁrst description of aggrecanase activity in human samples18
therefore subtracted 19 residues from the database numbering so
as to describe the cleavage site in terms of the natural N-terminal.
Taking the numbering directly from the database for all species in
the future should eliminate this unnecessary confusion.ﬂuids of multiple species (major bands at 150e250 kDa
and 40e60 kDa) bearing this N-terminal24. Puriﬁcation of
these ﬂuids by CsCl gradient centrifugation and more de-
tailed structural analysis13 showed that the immunoreactive
fragments were of very low buoyant density despite their ap-
parent large size on SDS-PAGE. These authors concluded
that MMP-mediated aggrecanolysis can be independent of
aggrecanase activity (which cleaves intact aggrecan), in
that the MMPs uniquely degrade aggrecan molecules which
have already been C-terminally cleaved at unidentiﬁed sites
by unidentiﬁed proteinases (marked with ? in Fig. 2). Stud-
ies in cartilage explants with a monoclonal Ab (BC-14) to
361FFGVGG supported this general conclusion9.
The human aggrecanase cleavage products were ﬁrst
described in 199218 in a study where the N-terminal se-
quence on the high molecular weight CS-substituted aggre-
can from synovial ﬂuids of four patients (two early postinjury
and two late-stage OA) was found to be exclusively
393ARGSVI. This was followed by the same ﬁnding in joint
ﬂuids from eight patients with joint-injury and seven with in-
ﬂammatory joint diseases diagnosed as osteochondritis,
acute calcium pyrophosphate deposition disease, reactive
arthritis, psoriatic arthritis and juvenile RA25. A monoclonal
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Fig. 2. Molecular model describing the aggrecanase and MMP-
mediated pathways of aggrecanolysis. Aggrecan substrates are
to the left and products to the right. Aggrecan is shown as
composed of three globular domains (G1, G2, G3) connected by
a linear peptide. The IGD is between G1 and G2 and the GAG-at-
tachment regions (keratan sulfate and chondroitin sulfate) are
between G2 and G3. GAGs are not shown to simplify the diagram.
Terminal sequences have been experimentally identiﬁed (as shown)
except for the C-terminals of the MMP pathway, which are shown as
a question mark.
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these species in bovine and porcine cartilage explant sys-
tems9, but it does not appear to have been used with hu-
man products. Instead, polyclonal antibodies have been
used in this regard15 and an important new monoclonal
Ab (OA-1) to this N-terminal is described in the paper of
Struglics et al.16. The development of neoepitope antibod-
ies to NITEGE39226 was followed by demonstration of the
presence of the G1-NITEGE392 product in human synovial
ﬂuids27 and articular cartilages14. Most recently, in a detailed
Western analysis of synovial ﬂuids and cartilages from joint-
injured and late stage OA patients15, we concluded that ag-
grecanase activity is exclusively responsible for the catabolic
turnover and release of large GAG-bearing fragments of ag-
grecan in human joints.
A working model of aggrecanolysis
in human cartilages
The available data therefore suggest a working model
(see Fig. 2) in which aggrecanase cleaves full-length mole-
cules (G1eG2eG3) and generates the three components
G1-NITEGE, ARGSVI-G2-TASELE and GRGTIG-G3. The
GRGTIG-G3 can be further cleaved at three other sites by
aggrecanase in vivo15. This is clearly destructive aggreca-
nolysis and would be expected to lead directly to depletion
of aggrecan (GAG) from the tissue. On the other hand, in
this model MMP-mediated cleavages are considered to be
independent of aggrecanase activity (at least in the patients
examined13,24), and conﬁned to the N-terminal globular do-
mains which have already lost the GAG-attachment re-
gions. MMP-mediated aggrecanolysis does not therefore
appear to be responsible for depletion of osmotically active
aggrecan from the tissue. Instead, it causes the release of
small FFGVGG-positive fragments13 and variable amounts
of G1-VDIPEN product15,16,27.
Data with a new antibody suggest
an alternative model
The provocative paper published by Struglics et al.16
challenges the working model presented in Fig. 2. In this
new work, evidence is presented for a third pathway (see
Fig. 8 in Ref.16) in which MMPs are proposed to be active
against full-length aggrecan (G1eG2eG3) and therefore
at least partly responsible for GAG loss from the tissue. In
this model, the MMP and aggrecanase enzymes act se-
quentially (rather than independently), with the MMP cleav-
ing ﬁrst at N360-F361 and the aggrecanase secondarily at
sites in the CS-2 rich region, but not in the IGD. This new
model is based largely on the ﬁnding that human cartilage
extracts and human synovial ﬂuids contain high-buoyant
density high molecular weight aggrecan fragments
(300e400 kDa), which react with a polyclonal antiserum
(called anti-FFGV) raised to the N-terminal immunogen se-
quence 361FFGVGG. The authors conclude that the rela-
tive contributions of aggrecanase and MMP-mediated
destructive cleavage (with GAG loss) are about 58% and
22%, respectively.
Testing neoepitope speciﬁcity
Conclusions drawn from the new data16 require that tests
establish a robust speciﬁcity for the new antiserum. Indeedthe commonly accepted tests have been stringently applied
by Struglics et al. First, reactivity with MMP-products gener-
ated in vitro was shown to be eliminated by preadsorption of
the antiserum with the immunizing peptide but not with the
spanning peptide (see Fig. 216). A second test of the validity
of the Western data is that the size (kDa) of the FFGVGG-
reactive proteins can be shown to coincide with that of pro-
teins, which react with other antibodies expected to detect
the structure predicted. In this case, the FFGVGG-reactive
synovial ﬂuid products (Table 116) appeared (Fig. 416) to re-
act with anti-KEEE alone (335/341 kDa product) or anti-
SELE alone (310 kDa); the cartilage products (Table 116)
appeared (Fig. 616) to react with either no other antibodies
(411 kDa and 300 kDa) or with anti-KEEE alone (340
kDa). In this regard, it is a potential problem that the conclu-
sions are based on analysis at very high molecular weights,
where molecules of different structures but similar size may
comigrate. It will therefore be important to further examine
the reactivity of these products with anti-G2 and anti-G3
antibodies28, as well as monoclonal antibodies to the
FFGVG N-terminal (AF-2824 and BC-1429).
Neoepitope antibody validation and use
The new antibody used by Struglics et al.16 was raised in
rabbits by injection of the peptide FFGVGG conjugated to
a carrier protein and was apparently used on Western blots
without afﬁnity puriﬁcation of the IgG. One possible expla-
nation of the new data is that the antiserum contains immu-
noglobulins, which react not only with the predicted
neoepitope N-terminal phenylalanine (known to be critical
to antibody recognition22), but also with the ‘‘side’’ of the im-
munogen. The inability of the spanning peptide to block re-
activity is not alone sufﬁcient to exclude this possibility. We
have reported this problem previously15 with our anti-ARG
antibody raised against the immunogen ARGSVILTVKC
linked to carrier protein. In another example (Dr John
Mort, personal communication) the immunogen
CGGFVDIPEN generated antibodies, which detected the
expected neoepitope in aggrecan, but also detected Ca-
thepsin L due to the presence of the internal sequence
GFVDIP in this proteinase. This problem of potential non-
speciﬁc staining is of particular concern in immunohisto-
chemistry where parallel Western analysis is not available.
This observation raises the more general issue that many
anti-peptide antibodies may detect proteins, which are unre-
lated to the protein under study but are detected due to the
presence of identical sequence strings. This potential error
can be addressed by use of the BLAST similarity search op-
tion at http://ca.expasy.org/ (set on Mammalia with E thresh-
old at 1000). Proteins which contain sequence which is
identical to the immunogen at the tetrapeptide level and
above, clearly need to be considered as potential reactants
on Western blots and on immunohistochemical analysis.
For example, in the present case the immunogen FFGVGG
may generate antibodies reactive with mammalian proteins
which contain the internal sequence FGVGG (such as pro-
teins described in articles linked to PubMed ID numbers,
10702662 and 1775063).
On the other hand, the novel FFGVG-reactive species
(Table 116) may possibly represent G1-bearing aggrecan
forms of different migration properties. This alternative can-
not be excluded from the data shown in Fig. 416 where all of
the FFG-reactive bands migrate in an area of the gel which
is also diffusely reactive with anti-G1. Another possible ex-
planation for the presence of high molecular weight
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Fig. 3. Immunohistochemical imaging of the distribution of G1-NITEGE and G1-VDIPEN in human postinjury cartilage. Femoral notch cartilage
was removed at surgery for anterior cruciate ligament repair and formalin ﬁxed. Histological processing and immunohistochemical staining for
G1-NITEGE (left) and G1-VDIPEN (right) was done essentially as described41. The anti-VDIPEN antibody was generously provided by Dr
John Mort.FFGVG-reactive species in OA synovial ﬂuid (Fig. 416) and
OA cartilage extracts (Fig. 616) is that bona fide low molec-
ular weight FFGVG-reactive products (Fig. 2) are covalently
cross-linked to high-buoyant density aggrecan species.
Such non-reducible cross-linking of G2-bearing aggrecan
has been proposed to explain the unexpected migration be-
havior of an abundant naturally occurring calpain-generated
aggrecan product in mature bovine cartilage extracts28.
Such cross-linking may also explain the presence of high
molecular weight AF-28-positive species in porcine explant
studies30 although it cannot be excluded that chondroitin
sulfate-bearing species with an N-terminal of FFGVG are
present in those explant products.
In summary, these considerations strengthen the argu-
ment that structural analysis by single antibody reactivity
alone could be misleading and suggest that identiﬁcation
by multiple conﬁrmatory analytical criteria may be required
in future.
Our unpublished data relevant to the debate
One explanation given by the authors for the discrepancy
between their data16 and previous studies of human synovial
ﬂuids13,15,18,25, is that their analysis was done with ﬂuids
pooled from 100 patients ( post injury and OA), whereas
the earlier work was done with an insufﬁciently representa-
tive group. In this regard it should be noted that the pub-
lished studies18,25 report individual analyses on 19
patients. Recently we have prepared aggrecan from a syno-
vial ﬂuid pool (1 ml from 30 individual patients, joint-injured
and late OA) and, following the published protocol18, we
have obtained N-terminal sequence datab with a view to de-
termining the relative abundance of ARGSV and FFGVG in
pooled material. Inspection of the Edman data indicated
that a protein with N-terminal ARG was indeed present,
whereas there was no clear evidence for an N-terminal of
FFG since there was no phenylalanine in cycles 1 and 2.
A suitable internally controlled tool for determining the rela-
tive abundance of these two species is to compare the pmol
yield of valine (V) in the 4th and 5th cycles of Edman deg-
radation. Thus, valine in the 4th cycle is a measure of FFGV
and valine in the ﬁfth cycle is a measure of ARGSV. The
b This data was generated by Dr Scott McClung and Ran Zheng
at the Protein Sequencing Core Facility at the University of Florida.yields of valine in our pooled sample were found to be
1 pmol in cycle 4 and 131 pmol in cycle 5 also suggesting
that the FFGV product is absent whereas the ARGSV prod-
uct is abundant. It should also be noted that the high yield of
valine in cycle 5 may be partly due to the expected pres-
ence of the fragment from the CS-2 domain bearing the ag-
grecanase-generated N-terminal 1734GLGSV. Strict
quantitation of the relative abundance of N-terminal se-
quences in protein mixtures such as this is problematic
due to the high backgrounds generated from other proteins.
A more deﬁnitive answer to this question may be obtained
with a method based on proteolytic digestion of the mixture
and quantitation of mass-identiﬁed N-terminal peptides by
mass spectrometry.
The model proposed in Fig. 2 suggests that aggrecanase
generates G1-NITEGE by cleaving full-length aggrecan,
whereas MMPs generate G1-VDIPEN by cleaving a sepa-
rate pool of low molecular weight aggrecan only, suggesting
the possibility of distinct distribution patterns for G1-NITEGE
and G1-VDIPEN in the tissue. To investigate this further we
have done immunolocalization of these two species in con-
tiguous sections of notch cartilage from human postinjury
knee jointsc (Fig. 3). We present here some typical data.
The staining intensity for the two antibodies in the pericellu-
lar region of identical cells (arrows 1, 2, 3) appears to be sim-
ilar, however, the intensity for G1-NITEGE staining appears
much higher than G1-VDIPEN in the adjacent intercellular
matrix, as seen in the boxed areas 4 and 5. This relative dis-
tribution would be expected if G1-VDIPEN results primarily
from cell-associated MMP activity whereas G1-NITEGE is
formed both by a cell-associated and a diffusible form of ag-
grecanase. While further studies with quantitative confocal
analysis of epitope distribution is needed to substantiate
this idea, it is signiﬁcant that the relative abundance of the
two products suggested by the DAB immunostains (G1-NI-
TEGE\G1-VDIPEN) is consistent with the relative abun-
dance suggested by Western analysis of similar notch
biopsies15. It should also be noted that the afﬁnity puriﬁed
antibodies being used in these ongoing imaging studies
(anti-CGGNITEGE; JSCNIT; anti-CGGFVDIPEN, Mort
#1319) have been previously shown to react speciﬁcally
with G1-NITEGE392 and G1-VDIPEN360 on Western anal-
ysis of naturally occurring human aggrecan fragments15,31.
c This data was generated with human cartilage collected under
full IRB approval by Dr Fred Nelson at Henry Ford Hospital, Detroit.
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The new paper published by Struglics et al.16 represents
an important addition to the area and further work will
undoubtedly test the novel aggrecanolysis model they
have provided. The new data we provide and working
model we present (Fig. 2) are more in line with that
previously suggested by Fosang et al.13,24. In this scenario,
MMPs are not destructive but instead play an important
constructive role in modifying the composition of the
pericellular space. Such separation of the role of MMPs
(constructive) and aggrecanases (destructive) is clearly con-
sistent with much current thinking on the role of MMPs32.
It also provides an explanation for the ﬁnding that mice
with a null mutation in ADAMTS5 (aggrecanase-2) are pro-
tected from arthritic change33,34 whereas mice with null mu-
tations in MMP-3, and upstream activators of MMP activity in
cartilage (IL-1beta, ICE and iNOS), are more prone to arthrit-
ic change than wild-type animals35. Indeed, null mutations in
MT1-MMP36 and MMP-937 are very destructive to cartilage
matrix organization, growth and enchondral ossiﬁcation sug-
gesting that MMPs are required for, rather than destructive
toward, cartilage matrix homeostasis.
Thus, in terms of therapeutic control, it follows that block-
ade of MMPs may eliminate the normal pericellular remod-
eling of aggrecan and result in abnormal cellular responses.
Indeed, experiments should be done to determine whether
MMP blockade generates chondrocytes, which are hyper-
reactive to catabolic challenge. Our understanding of this
MMP-mediated pathway13 suggests that the MMP sub-
strates (Fig. 2) represent a discrete pool of G1-rich species
in the pericellular space. The proteinases responsible for
formation of this ‘‘remodeling’’ pool are unknown but it
seems likely that they will also be MMPs and/or calpains
since cleavages in appropriate locations have been identi-
ﬁed28. It appears that in arthritis, this pool is remodeled by
localized MMP activity at N360-F361 leading to the appear-
ance of the small FFGVGG-positive fragments in the ﬂuid13
and enrichment of G1-FVDIPEN360 in the tissue. Exactly
which MMP(s) are involved and the precise role(s) of the in-
termediates of the MMP-mediated pathway remains to be
discovered. In contrast to the MMP pathway, the model
(Fig. 2) proposes that the aggrecanase pathway is respon-
sible for aggrecan destruction, and therefore therapeutic
blockade of ADAMTS-mediated aggrecanolysis might be
expected to protect the tissue from matrix loss. Finally, it
has become clear that testing of the model proposed
by Struglics et al.16 and the alternative presented below in
Fig. 2 will require stringent investigation in both animal mod-
els and human tissues by the multiple technologies now
available. Current approaches include the combined use
of immunoreagents and confocal imaging technologies to
‘‘catch’’ the proteinases responsible for aggrecanolysis in
their precise tissue location at the time of aggrecan cleav-
age. These approaches should soon allow for identiﬁcation
of the speciﬁc members of the MMP and aggrecanase fam-
ilies, which are involved in these different aspects of human
cartilage aggrecanolysis. Hopefully, this will be followed by
the design of drugs to speciﬁcally interfere only with the pro-
teolytic events, which are destructive to the tissue.
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